… lung cancers—KRAS—… cancers without targetable mutations, those with targetable mutations
who have progressed through targeted therapy, and those with squamous cell lung cancers…

… Lung cancer remains the leading cause of cancer deaths in … been made in the science of
non–small cell lung cancer (NSCLC). … The National Lung Screening Trial found a lung cancer …

… of targeted treatments for patients with advanced non-small-cell lung cancer, especially
focusing … This is the third in a Series of three papers about lung cancer (paper 1 appears in The …

… of current findings in the cell biology of lung cancer as they pertain to the therapy of NSCLC.
… of adjuvant therapy on resected Stage II and III non-small cell carcinoma of the lung. Ann …

… lung cancer into 2 major classes based on its biology, therapy, and prognosis: NSCLC and
small cell lung cancer … in Oncology [NCCN Guidelines] on Small Cell Lung Cancer; for the …

… in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in
screening, diagnosis, and treatment. The advances in systemic treatment have been driven …

… from lung cancer than prostate, breast, and colorectal cancer combined (1). Approximately
85% of the patients with lung cancer will have non–small cell lung cancer (… , large cell, and not …

… of patients with non–small-cell lung cancer (some of whom had received previous therapy
and … clearly exceeds that anticipated with standard therapy, with median overall survival not …

… The WHO divides lung cancer into 2 major classes based on its … , therapy, and prognosis:
NSCLC and small cell lung cancer (see the NCCN Guidelines for Small Cell Lung Cancer, …

… Conventional treatment of non-small-cell lung cancer (NSCLC) has apparently reached a …
in the management of locally advanced and advanced disease, treatment outcomes for …